ArticleAIDS and behavior2025
Predictive Factors of ART Follow-Up Loss in HIV Patients (2018-2022): A Retrospective Cohort Study.
Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Loss to follow-up (LTFU) in antiretroviral therapy (ART) poses significant challenges in the management of HIV/AIDS. This study aims to identify socio-demographic and clinical factors influencing LTFU among patients undergoing ART in Luzhou, China, and to develop a predictive model for LTFU using Cox risk regression analysis. In this retrospective cohort study, data from 8,770 patients diagnosed with HIV infection between January 1, 2018 and December 31, 2022 who were enrolled in the national free ART program were analyzed. The primary outcome was the first occurrence of LTFU. Cox proportional risk regression analyses were conducted to identify predictors of LTFU. The study population had a median age of 64.25 years, and 73.2% were male. The overall LTFU rate was 4.14 per 100 person-years. Factors associated with a decreased likelihood of LTFU included female gender, homosexual transmission, absence of HIV-related diseases, negative HBV surface antigen, higher final CD4 count, and an increase in CD4 count from baseline. In contrast, older age, longer time from diagnosis to ART initiation, higher baseline viral load, missed medication doses, and the development of medication side-effects were associated with an increased risk of LTFU. Our prediction model identifying the risk of loss to follow-up demonstrated good predictive performance with a C-index of 0.721. The study highlights the importance of considering a range of socio-demographic and clinical factors in managing LTFU among people living with HIV (PLHIV) on ART. Our prediction model can be a valuable tool for healthcare providers to identify patients at high risk of LTFU, facilitating targeted interventions to improve treatment adherence and outcomes.
Indexed as
Identifiers
39739283What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.